TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga Logo Benzinga By Vandana Singh
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

CRISPR Therapeutics reported positive Phase 1 trial results for CTX310, an investigational gene therapy targeting ANGPTL3, demonstrating significant lipid-lowering effects with a single treatment and no serious adverse events.

Insights
CRSP   positive

Demonstrated promising clinical trial results with dose-dependent lipid reduction and no serious adverse events